Julia D. Maltzman

SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis

Ruben A. Mesa, Jean‐Jacques Kiladjian, John Catalano et al. · Journal of Clinical Oncology · 2017 · 345 citations · Full text

Hematological Malignancy, Immunohematology, Momelotinib 200 +13

Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial

Claire Harrison, Alessandro M. Vannucchi, Uwe Platzbecker et al. · The Lancet Haematology · 2017 · 301 citations

Hematological Malignancy, Momelotinib Versus, Simplify 2 +5

Phase II Clinical Trial of Amatuximab, a Chimeric Antimesothelin Antibody with Pemetrexed and Cisplatin in Advanced Unresectable Pleural Mesothelioma

Raffit Hassan, Hedy L. Kindler, Thierry Jahan et al. · Clinical Cancer Research · 2014 · 182 citations · Full text

Folate receptor alpha (FRA) expression in breast cancer: identification of a new molecular subtype and association with triple negative disease

Daniel J. O’Shannessy, Elizabeth B. Somers, Julia D. Maltzman et al. · SpringerPlus · 2012 · 156 citations · Full text

Breast Oncology, Pathology, Cancer Biology +16

Folate Receptor-α (FOLR1) Expression and Function in Triple Negative Tumors

Brian M. Necela, Jennifer A. Crozier, Cathy Andorfer et al. · PLoS ONE · 2015 · 145 citations · Full text